SCHEMBL620145

SCHEMBL620145

Cc1cc(=O)c2c(O)cccc2o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.64
ALOX15 P16050 3/20 0.64
CYP1A2 P05177 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
KDM4E B2RXH2 2/20 0.64
RECQL P46063 2/20 0.64
HSD17B10 Q99714 2/20 0.64
LMNA P02545 1/20 0.64
TP53 P04637 1/20 0.64
POLB P06746 1/20 0.64
GAA P10253 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
AR P10275 8/20 0.62
ATM Q13315 1/20 0.60
PTGS1 P23219 2/20 0.59
PTGS2 P35354 2/20 0.59
CYP3A4 P08684 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
ALDH1A1 P00352 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31670262 1.00 MAPT (0.64) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL30087046 0.81 MAPT (0.53) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL20886870 0.81 MAPT (0.53) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL31398703 0.79 AR (0.55) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
Noreugenin SCHEMBL29370130 0.78 PTGS2 (0.71) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL29854712 0.78 AR (0.58) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
Noreugenin SCHEMBL168822 0.78 PTGS2 (0.71) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL13717866 0.78 AR (0.58) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL15920417 0.77 POLH (0.58) MAPTALOX15CYP1A2SMN1; SMN2KDM4E
SCHEMBL14752570 0.77 ALOX15 (0.57) MAPTALOX15CYP1A2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10244779-B2 Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer SENOMYX, INC. (US) 2019-04-02 US claimed
CN-106107406-A Improve the method for the stability of sweetness enhancers and comprise the compositions of stable sweetness enhancers 赛诺米克斯公司 2016-11-16 CN claimed
US-20150245642-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED 2015-09-03 US claimed
EP-2603098-A2 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER Senomyx, Inc. (US) 2013-06-19 EP claimed
CN-103153096-A Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers SENOMYX INC 2013-06-12 CN claimed
US-20120041078-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER SENOMYX, INC. (US) 2012-02-16 US claimed
WO-2012021837-A2 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER SENOMYX, INC. (US) 2012-02-16 WO claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP disclosed
CN-115724816-B Chromone crystal form in mangrove-derived fungi and preparation and application thereof 海南师范大学 2023-11-24 CN disclosed
CN-115490661-B Antioxidant active compound in mangrove-derived fungi and preparation method thereof 海南师范大学 2023-09-08 CN disclosed
CN-115724816-A Crystal form of chromone in mangrove-derived fungi, preparation and application thereof 海南师范大学 2023-03-03 CN disclosed
CN-115490661-A Antioxidant active compound in mangrove-derived fungi and preparation method thereof 海南师范大学 2022-12-20 CN disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
EP-1508327-A1 Use of chromen-4-one derivatives for the care of skin and hair MERCK PATENT GmbH (DE) 2005-02-23 EP disclosed
EP-0430693-B1 Pyrimidinedione derivative compounds, method for preparing same, and antiarrhythmic agents containing same MITSUI TOATSU CHEMICALS (JP) 1995-05-31 EP disclosed
US-5114941-A PYRIMIDINEDIONE DERIVATIVE COMPOUNDS, METHOD FOR PREPARING SAME, AND ANTIARRYTHMIC AGENTS CONTAINING SAME MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-19 US disclosed
EP-0430693-A2 Pyrimidinedione derivative compounds, method for preparing same, and antiarrhythmic agents containing same MITSUI TOATSU CHEMICALS, Inc. (JP) 1991-06-05 EP disclosed
US-4105781-A ANTIALLERGENS FOR TREATMENT OF ASTHMA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1978-08-08 US disclosed
US-4049664-A ANTIALLERGENS, ANTIASTHMATICS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-09-20 US disclosed
US-3965122-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10244779-B2 Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer TFEB, TREH, SLC2A8 MAPT 1864/4885ALOX15 2796/4885CYP1A2 4854/4885
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB MAPT 1946/4885ALOX15 3919/4885CYP1A2 4618/4885
US-20120041078-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER TFEB, TREH, SLC2A8 MAPT 1864/4885ALOX15 2796/4885CYP1A2 4854/4885
US-20150245642-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER TFEB, TREH, SLC2A8 MAPT 1864/4885ALOX15 2796/4885CYP1A2 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.